According to a quite diffuse opinion, also amplified by the media, the serologic test has a limited diagnostic value and is of no use as an indication to the booster dose of a COVID-19 vaccine. In addition, this point of view was strengthened by a hasting criticism, which appeared in television, social networks and newspapers and was based on a personal interpretation of a paper published in NEJM Oct 2021. The current article shows how the NEJM paper asserts just the opposite thesis, supporting

more »

... the serologic test instead. Details are here provided, especially about the effective antibody/infectivity correlation and the possible threshold value between diseased and healthy people. The conclusion is that the NEJM paper strongly supports the serologic test, while the quick criticism derived from a biased lecture, in search of the confirmation of a preconception.